Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Lack of evidence of isoniazid efficacy for the treatment of MDR/XDR-TB in the presence of the katG 315T mutation

Dumitru Chesov, Nelly Ciobanu, Christoph Lange, Thomas Schön, Jan Heyckendorf, Valeriu Crudu
European Respiratory Journal 2017 50: 1701752; DOI: 10.1183/13993003.01752-2017
Dumitru Chesov
1Dept of Pneumology and Allergology, State University of Medicine and Pharmacy “Nicolae Testemitanu”, Chişinău, Republic of Moldova
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: dumitru.chesov@usmf.md
Nelly Ciobanu
2National TB Reference Laboratory, Phthisiopneumology Institute “Chiril Draganiuc”, Chişinău, Republic of Moldova
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christoph Lange
3Division of Clinical Infectious Diseases, German Center for Infection Research (DZIF), Research Center Borstel, Borstel, Germany
4International Health/Infectious Diseases, University of Lübeck, Lübeck, Germany
5Dept of Medicine, Karolinska Institute, Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Schön
6Dept of Infectious Diseases and Clinical Microbiology, Kalmar County Hospital, Kalmar, Sweden
7Dept of Clinical and Experimental Medicine, Division of Medical Microbiology, Linköping University, Linköping, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jan Heyckendorf
3Division of Clinical Infectious Diseases, German Center for Infection Research (DZIF), Research Center Borstel, Borstel, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jan Heyckendorf
Valeriu Crudu
2National TB Reference Laboratory, Phthisiopneumology Institute “Chiril Draganiuc”, Chişinău, Republic of Moldova
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Further studies are needed to address the possible benefits of high-dose isoniazid therapy adequately http://ow.ly/XDcd30fiFeR

To the Editor:

We are grateful for the response by E. Heldal to our correspondence. Similar to other reports [1] from the World Health Organization (WHO) Euro-Region we found that a high proportion (88%) of Mycobacterium tuberculosis strains from patients with multidrug-resistant (MDR)/extensively drug-resistant (XDR) tuberculosis (TB) in the Republic of Moldova had a katG 315T mutation, which is strongly suggestive that high-dose isoniazid should not be part of a standardised treatment regimen for patients with MDR/XDR-TB in this country.

We respectfully disagree with the conclusion made by E. Heldal, as related to the presence of the katG 315T mutation, that “…a majority of strains with low or moderate-level resistance can be effectively treated with isoniazid at normal or high doses…” as this statement is not sufficiently supported by the scientific literature.

In 2011 the Clinical and Laboratory Standards Institute (CLSI) defined a breakpoint for isoniazid at 0.2 mg·L−1 for Middlebrook 7H10 media [2]. CLSI also set 1 mg·L−1 as an additional breakpoint in order to define low-level resistance and identify patients that may possibly profit from high-dose isoniazid treatment. Full range minimum inhibitory concentration (MIC) testing in 7H10 showed an MIC distribution from 0.032 to 0.125 mg·L−1 for wild-type isolates (n=79) [3]. In a recent cohort of patients with MDR/XDR-TB from Germany and Sweden, all 18 strains of M. tuberculosis with a mutation in katG 315T had an MIC for isoniazid of >3 mg·L−1 in liquid culture (MGIT) (J. Heyckendorf and co-workers, unpublished results). In 52 additional isolates with katG 315T mutations without other known resistance mechanisms for isoniazid, MICs were found to be between 4 and 32 mg·L−1 on Middlebrook 7H10 media (T. Schön and co-workers, unpublished results). In 27 of these 52 katG 315T mutated isolates the MICs for isoniazid were 8 mg·L−1. Thus, most isolates with a katG 315T mutation showed MICs at least 30 times higher than current breakpoints and wild-type isolates and not a single strain out of 68 tested M. tuberculosis strains with isoniazid resistance due to a mutation in katG 315 had a MIC <3 mg·L−1 by two different methods.

In the correspondence by Otto-Knapp et al. [4], referred to by E. Heldal as a study which indicates that strains with katG 315T mutations have highly variable MICs, the authors defined intermediate level drug resistance to isoniazid by an MIC of >1 and <5 mg·L−1 using Middlebrook 7H10 agar. The concentrations tested and the presence of other isoniazid resistance mechanisms in these isolates is not mentioned in further detail. We are unaware of an international consensus or standards on the definition of intermediate drug resistance to isoniazid within this MIC range. Furthermore, the suggestion in the same report [4] that isoniazid or any anti-tuberculosis drug is effective just if maximum serum concentrations are above the in vitro generated MIC is, to our knowledge, not supported by clinical data, nor is it consistent with current concepts of establishing clinical breakpoints [5]. The pharmacokinetic and pharmacodynamic (PK/PD) target for isoniazid needed to obtain a clinical cure has yet to be established. When considering treatment of isolates with resistance mutations and elevated MICs against isoniazid, pharmacokinetic variability should be taken into account as it strongly influences PK/PD ratios [6]. In contrast to other pathogens, clinical breakpoints including an intermediate range are not established for tuberculosis and should be based on MIC distributions, PK/PD-analysis and clinical outcome data [5].

In patients with isoniazid-monoresistant TB it appears that different levels of isoniazid resistance do not substantially affect TB treatment outcomes. In one study with 134 patients with culture-confirmed isoniazid-monoresistant TB, treatment success rates were similar (81.8% versus 86.7%) between low- and high-concentration isoniazid-resistant TB [7]. In another study with 395 patients with culture-confirmed isoniazid-monoresistant pulmonary TB, the treatment success rates were also similar in patients with high-level and low-level isoniazid-resistant TB (82.2% versus 83.4%) and among those taking anti-tuberculosis treatment with and without isoniazid (83.1% versus 83.0%) [8]. Of note, a cut-off of >1 mg·L−1 was used to define high-level isoniazid resistance in both of these trials and drug concentrations were not measured. In patients with isoniazid-resistant TB, bacillary mutations in katG 315T, but not in the inhA promotor, have been associated with unfavourable treatment outcomes [9].

The TBNET/RESIST-TB consensus statement highlights that evidence is lacking as to whether adding isoniazid to an MDR/XDR-TB regimen improves treatment outcomes when the genetic basis of the isoniazid resistance is a mutation in katG 315T [10]. Without sufficient evidence, high-dose isoniazid should not be given to patients with MDR/XDR-TB carrying strains with katG 315 mutations since the risk of toxicity may outweigh the potential benefit. Individualised therapy based on comprehensive drug susceptibility testing (DST) appears to be a more promising technique to improve therapy outcomes in MDR/XDR-TB. Early bactericidal activity studies with high-dose isoniazid in MDR/XDR-TB and clinical studies evaluating treatment outcomes in MDR/XDR-TB in patients randomised to receive high-dose isoniazid or a placebo in addition to a DST-guided regimen are needed to address the possible benefits of high-dose isoniazid therapy adequately.

Disclosures

Supplementary Material

D. Chesov ERJ-01752-2017_Chesov

J. Heyckendorf ERJ-01752-2017_Heyckendorf

C. Lange ERJ-01752-2017_Lange

Footnotes

  • Conflict of interest: Disclosures can be found alongside this article at erj.ersjournals.com

  • Received August 26, 2017.
  • Accepted August 29, 2017.
  • Copyright ©ERS 2017

References

  1. ↵
    1. van Leth F,
    2. Guenther G,
    3. Hoffmann H
    , et al. Reply from the authors of limited benefit of the new shorter MDR-TB regimen in Europe. Am J Respir Crit Care Med 2017; in press [https://doi.org/10.1164/rccm.201705-0995LE].
  2. ↵
    1. Clinical and Laboratory Standards Institute
    . Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes; approved standard. Wayne, CLSI, 2011.
  3. ↵
    1. Schön T,
    2. Jureen P,
    3. Giske CG
    , et al. Evaluation of wild-type MIC distributions as a tool for determination of clinical breakpoints for Mycobacterium tuberculosis. J Antimicrob Chemother 2009; 64: 786–793.
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    1. Otto-Knapp R,
    2. Vesenbeckh S,
    3. Schönfeld N
    , et al. Isoniazid minimal inhibitory concentrations of tuberculosis strains with katG mutation. Int J Tuberc Lung Dis 2016; 20: 1275–1278.
    OpenUrl
  5. ↵
    1. Kahlmeter G
    . The 2014 Garrod Lecture: EUCAST–are we heading towards international agreement? J Antimicrob Chemother 2015; 70: 2427–2439.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Pasipanodya JG,
    2. McIlleron H,
    3. Burger A
    , et al. Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis 2013; 208: 1464–1473.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Wang TY,
    2. Lin SM,
    3. Shie SS
    , et al. Clinical characteristics and treatment outcomes of patients with low- and high-concentration isoniazid-monoresistant tuberculosis. PLoS One 2014; 9: e86316.
    OpenUrl
  8. ↵
    1. Chien JY,
    2. Chen YT,
    3. Wu SG
    , et al. Treatment outcome of patients with isoniazid mono-resistant tuberculosis. Clin Microbiol Infect 2015; 21: 59–68.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Huyen MNT,
    2. Cobelens FGJ,
    3. Buu TN
    , et al. Epidemiology of isoniazid resistance mutations and their effect on tuberculosis treatment outcomes. Antimicrob Agents Chemother 2013; 57: 3620–3627.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Domínguez J,
    2. Boettger EC,
    3. Cirillo D
    , et al. Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a TBNET/RESIST-TB consensus statement. Int J Tuberc Lung Dis 2016; 20: 24–42.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top
View this article with LENS
Vol 50 Issue 4 Table of Contents
European Respiratory Journal: 50 (4)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Lack of evidence of isoniazid efficacy for the treatment of MDR/XDR-TB in the presence of the katG 315T mutation
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Lack of evidence of isoniazid efficacy for the treatment of MDR/XDR-TB in the presence of the katG 315T mutation
Dumitru Chesov, Nelly Ciobanu, Christoph Lange, Thomas Schön, Jan Heyckendorf, Valeriu Crudu
European Respiratory Journal Oct 2017, 50 (4) 1701752; DOI: 10.1183/13993003.01752-2017

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Lack of evidence of isoniazid efficacy for the treatment of MDR/XDR-TB in the presence of the katG 315T mutation
Dumitru Chesov, Nelly Ciobanu, Christoph Lange, Thomas Schön, Jan Heyckendorf, Valeriu Crudu
European Respiratory Journal Oct 2017, 50 (4) 1701752; DOI: 10.1183/13993003.01752-2017
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Disclosures
    • Footnotes
    • References
  • Info & Metrics
  • PDF

Subjects

  • Respiratory infections and tuberculosis
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Agora

  • Polyurethane foam degradation in CPAP devices for sleep apnoea
  • P. aeruginosa membrane vesicles cause endothelial barrier failure
  • Mortality after admission with pneumonia higher than after admission with COPD exacerbation
Show more Agora

Correspondence

  • Extracorporeal life support as a bridge to lung transplantation strategy in anti-MDA5+ rapidly progressive interstitial lung disease is life-saving but with persistent difficulties at the bedside
  • Liver cancer in severe alpha-1 antitrypsin deficiency: Who is at risk?
  • Cancer risk in severe alpha-1-antitrypsin deficiency - the importance of the early identification
Show more Correspondence

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2022 by the European Respiratory Society